embecta-sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir

Rhea-AI Summary

Embecta presented two abstracts at the ADA's 84th Scientific Sessions, highlighting the potential benefits of a 300-unit insulin reservoir patch pump for adults with type 2 diabetes (T2D). Research indicated that the larger reservoir could reduce the need for frequent patch changes and better accommodate daily insulin needs. One study found that insulin total daily dose (TDD) was influenced by factors such as BMI and medication type. Another analysis showed that a 300u reservoir would meet the needs of 64% of T2D patients for 72-hour wear compared to 38% for a 200u reservoir. Embecta has submitted a 300u insulin delivery system to the FDA for approval.

Positive

• Presented data at ADA's 84th Scientific Sessions, enhancing company visibility.
• 300u insulin reservoir patch pump could meet the needs of 64% of T2D patients for 72-hour wear.
• Embecta submitted a 300u insulin delivery system to the FDA for approval, indicating potential future product availability.
• Study showed larger reservoir patch pumps reduce frequency and cost of changing disposable pumps.

Negative

• Data showed insulin TDD was lower among African Americans and women, possibly indicating unequal treatment efficacy.
• Only 38% of T2D patients' needs would be met by a 200u insulin reservoir for 72-hour wear, highlighting limitations of smaller reservoirs.

PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association’s 84^th Scientific Sessions that point to the potential for adults with type 2 diabetes (T2D) to better manage insulin delivery through a patch pump with a larger, 300-unit (u) insulin reservoir, which could provide longer wear times and fewer disposable patches over time.

In “Predictors of Insulin Total Daily Dose (TDD) in U.S. Adults with T2D on Multiple Daily Injections (MDI),” Viral N. Shah, M.D., Professor of Medicine, Division of Endocrinology & Metabolism and Director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University School of Medicine, and his co-authors analyzed 41,215 adults with T2D on multiple daily insulin injections who were prescribed a mean insulin TDD of 96 units of insulin to investigate demographic and clinical factors that could impact insulin dosage. The authors concluded that insulin TDD was greater by 3% for each unit increase in body mass index (BMI) and 8% and 12% higher among those prescribed an SGLT-2 inhibitor and GLP-1RA respectively at baseline. TDD was lower by 2%, 8% and 20% among adults prescribed 1, 2 or 3 non-insulin medications before the index TDD date respectively. Moreover, TDD was 15% lower among African Americans vs. Caucasians and 7% lower in women than men.

In “Evaluating Need for Larger Insulin Reservoir in Patch Pumps: Leveraging Retrospective Dose Data for US Adults with T2D on MDI,” Eugene E. Wright Jr., M.D., Medical Director, South Piedmont Area Health Education Center, and co-authors analyzed adults with T2D on multiple daily injection therapy, estimating the number of people for whom 200u and 300u insulin reservoirs would be sufficient for different wear times and the number of patch pumps needed over time.

“Based on the mean total daily dose of 96±58 units of insulin per day in a cohort of 41,215 adults with T2D on MDI (> 3 injections per day), we noted that a 300u insulin reservoir would meet the needs of 64% of adults with T2D for 72-hour wear, while a 200u reservoir would only meet the needs of 38% of that same population,” said Dr. Wright. Moreover, based on the mean TDD, the number of patch pumps suitable for 72-hour wear per month for a 200u vs 300u reservoir are 15 vs. 10 respectively. “With the option of a larger insulin reservoir size, people with type 2 diabetes who are currently using approximately the mean dose of daily insulin may consider transitioning from MDI to a patch pump without the cost and inconvenience of changing the disposable pump every day or two.”

"The data presented at the ADA Scientific Sessions this weekend reaffirms what we’ve learned from speaking with people living with diabetes and their healthcare providers: there is a critical unmet need among the T2D population for pumps with a larger insulin reservoir,” said Henry Anhalt, D.O., Chief Medical Officer, embecta. “As our mission is to make life better for people living with diabetes, we prioritized a 300u reservoir in the proprietary disposable insulin delivery system we submitted earlier this year to the U.S. Food and Drug Administration (FDA) in a 510(k) premarket filing.”

The ADA’s 84^th Scientific Sessions are taking place June 21-24, 2024, in Orlando, Florida, and are accessible virtually.

About embecta 
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

Media	Investors
Christian Glazar	Pravesh Khandelwal
Sr. Director, Corporate Communications	VP, Head of Investor Relations
908-821-6922	551-264-6547
Contact Media Relations	Contact IR

FAQ

What did Embecta present at the ADA's 84th Scientific Sessions?

Embecta presented two abstracts highlighting the benefits of a 300-unit insulin reservoir patch pump for better management of insulin delivery in adults with type 2 diabetes.

How does the 300u insulin reservoir benefit T2D patients?

The 300u insulin reservoir could reduce the frequency and cost of changing disposable pumps, meeting the needs of 64% of T2D patients for a 72-hour wear period.

What factors influence insulin total daily dose (TDD) in T2D patients?

BMI, medication type, race, and gender influence insulin TDD, with higher TDD associated with higher BMI and certain medications, and lower TDD among African Americans and women.

What are the limitations of the 200u insulin reservoir for T2D patients?

The 200u insulin reservoir would only meet the needs of 38% of T2D patients for a 72-hour wear period, requiring more frequent changes compared to the 300u reservoir.

Has Embecta submitted the 300u insulin delivery system for approval?

Yes, Embecta has submitted the 300u insulin delivery system to the FDA for 510(k) premarket approval.